BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36732592)

  • 21. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Cancer; 2019 Jun; 19(1):605. PubMed ID: 31221124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status.
    Løvig T; Meling GI; Diep CB; Thorstensen L; Norheim Andersen S; Lothe RA; Rognum TO
    Scand J Gastroenterol; 2002 Oct; 37(10):1184-93. PubMed ID: 12408524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
    Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
    Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
    Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
    BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
    Wang D; Chen X; Du Y; Li X; Ying L; Lu Y; Shen B; Gao X; Yi X; Xia X; Sui X; Shu Y
    Front Immunol; 2022; 13():799988. PubMed ID: 35281032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
    Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
    Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer neoantigens as potential targets for immunotherapy.
    Ma W; Pham B; Li T
    Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.
    Scheel SK; Porzner M; Pfeiffer S; Ormanns S; Kirchner T; Jung A
    BMC Cancer; 2010 Aug; 10():413. PubMed ID: 20696052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frameshift mutations of a tumor suppressor gene ZNF292 in gastric and colorectal cancers with high microsatellite instability.
    Lee JH; Song SY; Kim MS; Yoo NJ; Lee SH
    APMIS; 2016 Jul; 124(7):556-60. PubMed ID: 27150435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells.
    Schwarz S; Schmitz J; Löffler MW; Ghosh M; Rammensee HG; Olshvang E; Markel M; Mockel-Tenbrinck N; Dzionek A; Krake S; Arslan B; Kampe KD; Wendt A; Bauer P; Mullins CS; Schlosser A; Linnebacher M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
    Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
    Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
    Kanemura H; Hayashi H; Tomida S; Tanizaki J; Suzuki S; Kawanaka Y; Tsuya A; Fukuda Y; Kaneda H; Kudo K; Takahama T; Imai R; Haratani K; Chiba Y; Otani T; Ito A; Sakai K; Nishio K; Nakagawa K
    JTO Clin Res Rep; 2022 Aug; 3(8):100373. PubMed ID: 35941997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.